Broadcaster Tunes In a 29% Surge on Deal Chatter

The airwaves are buzzing with news that a leading media company could be headed for a high-profile merger. If the numbers line up, this could be one of the most compelling deals in the sector this year. Read on to find out why.

While many are busy chasing the usual AI trends, a bigger opportunity is quietly brewing—and most are missing it.

Imagine a major shift in how and where AI is built, opening up incredible wealth opportunities for those in the know.

I’ve found 9 AI companies primed to lead this change.

These aren’t the tired “AI hype” stocks; they’re companies with real US operations, proven revenue growth, and deep AI integration.

I’ve put all the details in a FREE report: "Top 9 AI Stocks For This Month." 

Inside you’ll discover:

…and 6 more game-changing companies!

The smart money is watching—and once they move, these stocks could soar. Don’t be the last to catch this wave.

Get Your FREE Copy Now

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Aftermarket Earnings:

Economic Reports:

How would it feel to double your money by this time next year?

From thousands of stocks, only 5 have emerged with the best chance to gain +100% or more in the months ahead.

You can see all five of these tickers — absolutely free.

Just download the newly released 5 Stocks Set to Double special report from Zacks.

While we can’t guarantee future performance, previous editions of this report have delivered gains of +175%, +498%, and even +673¹.

The newest picks could be just as profitable.

Act fast — this opportunity ends at MIDNIGHT TONIGHT.

Download the report now, absolutely free

UnitedHealth Group [UNH] has been caught in a sector-wide slump this year, with healthcare stocks lagging far behind the broader market.

At just over $250 a share, the stock trades near its lowest point in years, and at a P/E ratio of 10.86, it’s at one of the steepest discounts the sector has seen in three decades.

While headlines have been dominated by political pressure on drug pricing and pharmaceutical tariffs, the underlying business remains highly diversified. UnitedHealth’s four segments, UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, span insurance, data analytics, and pharmacy services.

This breadth gives the company stability even when one segment faces headwinds.

For long-term investors, current valuations could represent an attractive entry point. Historical cycles show that when healthcare trades at such a sharp discount to the S&P 500, a rebound often follows.

With earnings due later this quarter and expectations already muted, even a modest beat could re-rate the stock higher.

If the sector rotation narrative gains momentum, with capital shifting from high-flying tech to undervalued defensive names, UnitedHealth is likely to be one of the first stops for institutional money.

For now, patient buyers may be able to accumulate at levels not seen since before the pandemic.

Gilead Sciences [GILD] has spent much of the past year reshaping investor expectations, and it’s working. The company just raised its full-year product sales forecast and boosted its earnings guidance on the back of surging demand for its HIV treatments, led by its twice-yearly prevention shot Yeztugo.

Analysts are quickly recalibrating. Morgan Stanley now sees the stock heading to $143, while BMO, Oppenheimer, and UBS have all lifted their targets.

The core HIV portfolio is delivering 7% growth in product sales, with standout performance from Biktarvy and Descovy. Meanwhile, cell therapy, an area that has lagged, could get a boost if Anito-cel succeeds in multiple myeloma trials.

What sets Gilead apart now is the mix of stability and upside. HIV revenue is recurring and resilient, while oncology and other pipeline assets offer growth catalysts.

Trading near $119, Gilead is up nearly 60% over the past year but still sits below the average analyst price target.

With guidance moving higher and retail sentiment flipping bullish, the stock’s next leg may be driven by institutional flows repositioning into biopharma leaders.

For investors seeking a blend of dependable cash flows and targeted innovation, Gilead’s current trajectory offers both.

Short-term trades don’t have to be risky guesses.

With the right system, you can identify stocks with a statistical edge—and that’s exactly what this free report delivers.

Inside, you’ll find 7 top picks selected from a proven methodology that has beaten the S&P 500 by over 2X since 1988.

Only the highest-rated opportunities make the list, and we’re giving it to you at no cost.

Don’t miss your shot to trade with an edge.

Click now to claim your free copy of this exclusive list.

Media group Tegna [TGNA] is suddenly back on investor radar after reports that Nexstar Media Group is in advanced talks to acquire the company.

The stock surged to just under $20 on the news, closing the gap toward analysts’ longer-term targets.

The potential deal would expand Nexstar’s reach and could command a price near $24 per share, according to industry speculation, representing further upside from current levels.

For Tegna, the acquisition could unlock synergies in content production, advertising sales, and local market penetration, making the combined entity more competitive against streaming and digital platforms.

Regulatory hurdles remain, as prior takeover attempts faced FCC scrutiny. However, with a more consolidated broadcasting market and shifting consumption habits, the strategic rationale for a tie-up is strong.

Even if the deal falls through, Tegna’s valuation remains compelling at a P/E ratio under 6 and a dividend yield north of 3%.

Investors eyeing TGNA should view the current situation as a two-way win: a completed acquisition could deliver a quick premium, while an independent path might still re-rate the stock as management continues to streamline operations and adapt its content mix.

Either way, the story is no longer about a struggling broadcaster, it’s about an asset in play.

Sapiens International provides software solutions for the insurance industry, offering platforms for policy administration, claims management, and analytics. With a global footprint and steady client base, the company has been positioning itself as a core technology partner for insurers navigating digital transformation.

Shares are up more than 20% in premarket trading after reports that U.S. investment funds are in final-stage talks to acquire a controlling stake in the firm, potentially valuing it at up to $2.2 billion. If a deal is announced, it could not only unlock shareholder value in the short term but also accelerate Sapiens’ expansion under new ownership.

Rumble is a video platform and cloud service provider catering to creators and businesses seeking alternatives to mainstream platforms. Its infrastructure also supports data-intensive applications, making it a player in both streaming and cloud computing.

Premarket shares are up around 15% following confirmation of acquisition talks with Germany’s Northern Data, an AI cloud technology firm. The potential $1.17 billion deal would give Rumble access to GPU-heavy cloud assets and large-scale data center operations, all capabilities that could turbocharge its AI ambitions.

Albemarle is a major global lithium producer, supplying a critical raw material for electric vehicle batteries. It also operates in bromine and catalyst markets, but lithium remains its core growth driver.

Shares are up more than 10% premarket after Chinese battery giant CATL announced a shutdown at one of its key lithium mines, tightening supply. The timing follows Albemarle’s Q2 earnings beat and an analyst price target boost from Oppenheimer. While lithium pricing remains volatile, any sustained supply constraints could boost margins for producers like Albemarle.

The market is full of noise right now — volatility, trade tensions, and supply chain headaches are dominating headlines.

But amid the turbulence, opportunity is hiding in plain sight.

This exclusive free report reveals 7 stocks strategically positioned to grow in the face of global disruption.

They’re built for this moment — selected from booming sectors, backed by smart data, and supported by strategies professionals are using right now.

If you’re ready to stop reacting and start planning, this guide is for you.

Get your free copy here and uncover the 7 opportunities others are missing.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.